Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The fundraising they has was over subscribed by %400. With less than %45 in public hands,that is less than £2 Million pounds worth of shares. Any good news will make this share move fast.
ignore my last i didn't add on 59m placing just the 6m open offer .. doh. total shares after placing and consolidation will be 85890000 (85.8m) x 0.50p options exercise price = mcap £42m
maths isnt my strong point but i make it after consolidation and with the placing there will be @ 33.3m shares. If the sp hits 50p then the mcap would be in the region of £16.6m . That is dirt cheap once the test is on the market and with a potential market size of £4.2 billion. Adam knows what he doing here.
Not sure where i got 10 for 1. THAT, the Company’s ordinary share capital be consolidated so that every 100 Existing Ordinary Shares held by a Shareholder at the date hereof be and is hereby consolidated into 1 New Ordinary Share.
Ok fair enough,did not read the official document,took the info from another site. Share price would still have to increase by over %200 for directors to use them.
The director has a proven track record of turning companies around. He did a interview on directors talks website. He has been approached by other companies in difficulty & has turned a few down. He will only take on companies which he believes can be saved & allot of potential to grow.
Think you got your decimal point in the wrong place. What i posted was correct. Got it from BrockermanDaniel. Current share price is .16 & not 16P. Your out by %1000. Option price is .5P. Anyone else wish the clarify this? Look at the current share price,what are the chances of it getting to 50p? However with the name change there will be a share consolidation, 10 for 1,so new exercise price will be 5p.
Just to clarify - it's not a drug per se. It's a test, a process that is non invasive. If people are thinking it's a wonder drug that can be cheaply replicated and under cut it's not.
exercise price is 50p not 5p . placing is at 0.11 = 11p
You and jeaniehow have both taken a strange venture into this share. Good luck to you both.
it is very strange that i invest in VIY a company in the oil sector, start a PhD in molecular biology designing a test, and then then VIY changes to a biotech commercialising a molecular based test very excited to see how a product can go from development to commercialisation i think i will be holding in this one for a long time
I feel happy to be a part of this new venture. Having worked with children with Downs Syndrome I know how difficult it can be for parents and families to cope at times with these children. Although these children can be extremely lovable and caring, their brains have been damaged beyond repair and they can only expect to achieve a mental age of 11-13. For a drug such as this to identify these faulty genes before a child fully develops in the womb can give parents the knowledge and understanding of what future lies ahead. Whilst there may be competition ahead as to who can produce this drug cheaply and quickly, I'm sure Premaitha have a winning formula for correctly identifying the risk to women at a crucial time.
The directors have a incentive for this company to perform,other wise they will not be able to exercise there warrants at .50p. & it must stay above that level for over 30 days. However with they name change there will also be share consolidation 10 for one,so the exercise price will be 5P.
The highly qualified team of scientists and technicians at Premaitha are also currently undergoing IONA® Test development and design verification processes; target completion for this stage is by 30 September 2014. The clinical performance and commercialisation testing is then anticipated to be substantially complete by 31 December 2014 with expected commercial launch of the IONA® test to commence January 2015.
The deal with Premaitha Health will be done & dusted next month,we will then have the name change to Premaitha Health. We have a new director who have a proven track record of turning companies around. Allot should be happening in the coming months.
Gekko ........I believe they are expecting to get to market towards the end of this year ......2014 ?? !! I have posted here I will not be put off by a 6mths delay.
Biotechnology company Premaitha Health is doubling its Manchester workforce after relocating from Cambridge to tap into the region's talent pool. Share Share Tweet +1 Email Premaithia Health chief executive Dr Stephen Little Biotechnology company Premaitha Health is doubling its Manchester workforce after relocating from Cambridge to tap into the region's talent pool. Premaitha Health, which is led by chief executive Dr Stephen Little, is currently developing an application to carry out prenatal testing to assess whether an unborn baby has Down's Syndrome. Dr Little is a former AstraZeneca scientist who launched and later sold Manchester-based diagnostics specialist firm DxS in an £80m- plus deal to Qiagen, a quoted sampling and testing business, in 2009. He joined Premaitha as chief executive in January and said his immediate task was to relocate to the city to tap into its huge skills set in the science and research sector. He said: “The city has the best knowledge base for science, research and development, and as we took the company from research phase to the development stage, we needed to be in a city which has a growing reputation in the science sector and the skills set to match. “The universities here have a lot of talented people, but the city also has people with experience, which is what we need.” Premaitha currently employs 12 staff in Manchester, but hopes to more than double this to 25, as it looks to commercialise the application - called the IONA. The firm, which is moving to Manchester Science Park next week, will be recruiting technical staff including molecular diagnostic scientists as well as sales and administration staff. It has also been working with MIDAS as it looks to expand its operations. Premaitha is aiming to bring its product to market towards the end of next year. It said the IONA was an advanced testing system compared to the current prenatal screening tests, which can suffer from a lack of accuracy. This can lead to many women with healthy pregnancies being incorrectly identified as “at risk” and subject to invasive follow up tests, which could carry a risk to the foetus. The Premaitha test uses next generation molecular technology to carry out more specific assessment which is safe for the foetus, said Dr Little. He added: “This is very exciting time for the company, which is using leading cutting edge technology in the field of diagnostics to bring the product to market.”
AIM listed Vialogy (VIY) shares came back from suspension on Friday, closing the session at 0.16p after a £6.5 million placing at 0.11p. We took part in that placing and will be taking up our full entitlements in the open offer at 0.11p – we were already shareholders. I suggest that existing shareholders do the same (given how in the money they are already) and also buy a lot more in the market on Monday. Vialogy has bought molecular diagnostic company Premaitha by issuing 95 million shares at 0.11p (that is a £10.5 million price tag). It has raised another £6.5 million at 0.11p in a placing which was FOUR TIMES oversubscribed with a raft of institutions on board. The open offer will raise up to £700,000 more. Effectively the free float (since the vendors and institutions and those who backed the last placing cannot or will not flip) is c 10%, if that. The board now comprises the company rescuer Adam Reynolds, Stephen Little from Premaitha who is a very impressive chap but also David Evans. Do you remember Axis Shield? No wonder the funds were lining up to back this one. Premaitha is working on the final development and commercialisation of a non-invasive pre-natal screening test for Down's syndrome developed by Premaitha. This is a massive market. Assuming the Open Offer is fully taken up the market cap at 0.11p (there will be a 100 for 1 consolidation) is sub £20 million. At 0.15p it is c£27 million and the company will have cash of c£8 million. An £19 million EV for a company with this board set to tap into a market this big ($4.2 billion) looks far too low. This is not a classic value investment of the sort Steve Moore and I favour. There are obvious risks. But we chatted to Reynolds who seems confident that his generous 0ption package (priced at 0.1p) will kick in before very long. That would require the shares to trade at above 0.5p for 30 consecutive days. With an undemanding EV, a tight free float and Evans on board, I really would not bet against it. We will only sell 24 hours after giving Nifty Fifty readers advice to bank gains. Our initial target price is a cautious 0.36p to sell. The stance is strong buy at up to 0.23p. - See more at: http://www.shareprophets.advfn.com/views/5994/vialogy-reverse-takeover-placing-shares-unsuspended-strong-buy#sthash.yH6sB6H6.dpuf
next week we will be a whole new company with a new name and very exciting prospects the history of the sp will then be completely irrelevant. Viy will be in the ashes and the phoenix will rise - Premaitha : )
Should see allot more upside from here,the share price is not far from a all time low & is a bargain at this price.
I believe adam Reynolds was quoted saying this is the best deal he has ever done.. and he has a very impressive CV. general meeting next Thursday, 3 trading days before could see a lot of interest.
Shares in this company are in short supply. Only %45 in public hands. The company has been transformed before they came out of suspension. I believe they are currently working on a deal right now & news should come soon.
That speaks volumes to me. If Reynolds believes he can do this then I know that the Board are rolling their sleeves up and getting their hands dirty. Far better to invest in Companies that are known to be actually working for you than working against you! I’m in.
alogy. I’m in for a spin! Posted on June 26, 2014 Brokermandaniel Read all about it.As a general rule of thumb we here at the world’s most infamous, libellous blog don’t usually cover stocks outside of the oil & gas/mining sectors. So it should be a surprise to learn that after slating SOFTWARE & COMPUTER SERVICES AIM listed Vialogy (VIY) shares when the “other lot” were in charge we are now or should I say ‘I have now increased my original token holding” and here’s why. The new improved Vialogy came back from restructuring/suspension a far healthier body politick, the tumour that was killing the Company has been excised. There is new life and where’s there’s life there is hope. Especially when Institutions have piled in en-mass because the new ‘cheeky chappies’ in charge have done exactly what they’ve promised to do here, before, a turnaround, making money for share-holders. The company rescuers are Adam Reynolds, David Evans and Stephen Little from Premaitha. A well-respected triumvirate! Suggest those that are looking for a quick spin. Do their sums. The recent £6.5 million placing at 0.11p. was FOUR TIMES oversubscribed with a raft of institutions now on board. I never took part in that placing because I was too busy with other matters and no one approached me! But I have bought in at a significantly higher price. “Vialogy has conditionally acquired the entire issued share capital of Premaitha, which is a molecular diagnostic company. The consideration of £10.5 million is to be satisfied by the issue of 95,454,545 New Ordinary Shares at a price of 11 pence per share. The Company has raised £6.5 million (before expenses) by means of the Placing and intends to raise up to a further £0.7 million by means of the Open Offer. The net proceeds of the Placing and the Open Offer will be used to develop and commercialize the IONA® Test, a non-invasive pre-natal screening test for Down’s Syndrome developed by Premaitha, and for general working capital purposes. The Acquisition, if completed, is of sufficient size to constitute a reverse takeover under the AIM Rules and therefore is subject to the approval of shareholders at a General Meeting to be held at 11.00 a.m. on 3 July 2014 at the offices of Panmure Gordon (UK) Limited, One New Change, London EC4M 9AF” Premaitha are working on the final development and commercialisation of a non-invasive pre-natal screening test for Down’s syndrome developed by Premaitha. The market for this is very, very large. $4.2 billion. Once the consolidation and proposals go through basically a foregone conclusion Vialogy will have £8,000,000 million in cash. In order for Adam Reynolds to take his options package at 0.1p or 10p post consolidation Vialogy would have to have been trading at above 0.5p or 50p post consolidation for 30 consecutive days. That
Global commercialisation plan The proposed customers for the IONA® Tests are the estimated 600 laboratories offering pre-natal screening within the EMEA region as well as similar labs throughout the rest of the world. Premaitha's primary channel to market will be through its own direct sales force targeting laboratory directors supported by activities to target and gain support of key opinion leaders. A secondary channel to market may be direct or indirect support from Premaitha's platform partners. The technology used in the IONA® Test will be new to many potential customers so Premaitha is in the process of establishing a demonstration laboratory at its Manchester headquarters. This laboratory will reproduce the complete IONA® Test workflow so that customers can test their own samples and be trained in the process. This laboratory will also act as a technical back-up which can provide testing should a customer have a problem in their own operation. Following the initial launch in Europe, the New Board intend to extend sales and marketing activities into Asia. There are no current plans to launch the IONA® Test in the USA. This is primarily due to the more stringent regulatory regime imposed by the FDA.